Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

Scott Spector

Head of Clinical Operations ompenaclid (RGX-202)

Scott is an accomplished clinical development executive with 20 years of pharmaceutical product development experience. He was previously the European President of Siro Clinpharm, an emerging market CRO with a strong emphasis on the CEE and India. His career in clinical development started at Quintiles Transnational, where he was instrumental in leading the growth of the company’s European operations. Scott served as the President of Quintiles France and Spain and was also the global operations head of the CNS and Anti-Infectives business units. Following a 10-year career at Quintiles, he became President of CAC Oncology, an early pioneer in oncology contract research services and drug development consulting. Upon the sale of CAC Oncology to AAIPharma, he became President of a newly created entity called AAI Oncology. He holds a BS/BA in Finance from Boston University and a Professional Certificate in Genetics and Genomics from Stanford University.